WO2014142521A1 - 발사르탄 및 로수바스타틴 칼슘을 포함하는 복합 제제 및 이의 제조방법 - Google Patents
발사르탄 및 로수바스타틴 칼슘을 포함하는 복합 제제 및 이의 제조방법 Download PDFInfo
- Publication number
- WO2014142521A1 WO2014142521A1 PCT/KR2014/002008 KR2014002008W WO2014142521A1 WO 2014142521 A1 WO2014142521 A1 WO 2014142521A1 KR 2014002008 W KR2014002008 W KR 2014002008W WO 2014142521 A1 WO2014142521 A1 WO 2014142521A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- valsartan
- rosuvastatin
- pharmaceutical composition
- rosuvastatin calcium
- calcium
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (16)
- 발사르탄(valsartan)과 로수바스타틴 칼슘(rosuvastatin calcium)을 활성 성분으로 포함하는 것을 특징으로 하는 심혈관계 질환 및 고지혈증 질환의 예방 또는 치료용 약제학적 조성물.
- 제 1 항에 있어서, 발사르탄과 로수바스타틴 칼슘이 분리된 상태로 존재하는 것을 특징으로 하는 약제학적 조성물.
- 제 2 항에 있어서, 발사르탄 과립에 로수바스타틴 칼슘이 혼합된 상태인 것을 특징으로 하는 약제학적 조성물.
- 제 3 항에 있어서, 발사르탄 과립 및 로수바스타틴 칼슘에 약제학적으로 허용 가능한 첨가제를 추가로 포함하는 것을 특징으로 하는 약제학적 조성물.
- 제 2 항에 있어서, 발사르탄과 로수바스타틴 칼슘이 각각 별개의 층에 존재하는 이층정 형태인 것을 특징으로 하는 약제학적 조성물.
- 제 1 항에 있어서, 로수바스타틴과 발사르탄을 1:2 내지 1:32의 중량비로 포함하는 것을 특징으로 하는 약제학적 조성물.
- 제 6 항에 있어서, 로수바스타틴과 발사르탄을 1:4, 1:8, 1:16 또는 1:32의 중량비로 포함하는 것을 특징으로 하는 약제학적 조성물.
- 제 7 항에 있어서, 약제학적 조성물이 정제이고, 1 정당 로수바스타틴 5 ㎎ + 발사르탄 80 ㎎, 로수바스타틴 5 ㎎ + 발사르탄 160 ㎎, 로수바스타틴 10 ㎎ + 발사르탄 80 ㎎, 로수바스타틴 10 ㎎ + 발사르탄 160 ㎎, 로수바스타틴 20 ㎎ + 발사르탄 80 ㎎, 또는 로수바스타틴 20 ㎎ + 발사르탄 160 ㎎을 포함하는 것을 특징으로 하는 약제학적 조성물.
- 제 1 항에 있어서, 협심증, 고혈압, 고지혈증, 동맥연축, 심부정맥, 심비대, 뇌경색, 울혈심부전 및 심근경색 중에서 선택된 하나 이상의 질환을 예방 또는 치료하기 위한 약제학적 조성물.
- (a) 발사르탄과 약제학적으로 허용 가능한 첨가제의 혼합물을 과립화하는 단계;(b) 로수바스타틴 칼슘과 약제학적으로 허용 가능한 첨가제를 단계 (a)의 발사르탄 과립에 혼합하는 단계를 포함하는, 심혈관계 질환 및 고지혈증 질환의 예방 또는 치료용 약제학적 조성물의 제조방법.
- 제 10 항에 있어서, (a) 단계에서 발사르탄 1 중량부당 약제학적으로 허용 가능한 첨가제 1 내지 3 중량부의 혼합물을 과립화하는 것을 특징으로 하는 제조방법.
- 제 10 항에 있어서, (b) 단계에서 로수바스타틴 칼슘 1 중량부당 약제학적으로 허용 가능한 첨가제 1 내지 10 중량부를 혼합하는 것을 특징으로 하는 제조방법.
- 발사르탄(valsartan)과 로수바스타틴 칼슘(rosuvastatin calcium)을 활성 성분으로 포함하는 것을 특징으로 하는 상승적 효과를 갖는 고혈압 치료용 약제학적 조성물.
- 제 13 항에 있어서, 조성물이 정제이고, 1 정당 발사르탄 160 ㎎ 및 로수바스타틴 20 ㎎을 포함하는 것을 특징으로 하는 조성물.
- 발사르탄(valsartan)과 로수바스타틴 칼슘(rosuvastatin calcium)을 활성 성분으로 포함하는 약제학적 조성물의, 심혈관계 질환 및 고지혈증 질환의 예방 또는 치료를 위한 용도.
- 발사르탄(valsartan)과 로수바스타틴 칼슘(rosuvastatin calcium)을 활성 성분으로 포함하는 약제학적 조성물을 필요로 하는 대상에 투여하는 단계를 포함하는, 심혈관계 질환 및 고지혈증 질환의 예방 또는 치료 방법.
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015562916A JP2016514125A (ja) | 2013-03-12 | 2014-03-11 | バルサルタン及びロスバスタチンカルシウムを含む複合製剤及びその製造方法 |
US14/775,422 US20160045497A1 (en) | 2013-03-12 | 2014-03-11 | Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor |
RU2015143218A RU2663460C2 (ru) | 2013-03-12 | 2014-03-11 | Комбинированный препарат, содержащий валсартан и розувастатин кальция и способ его изготовления |
AU2014230304A AU2014230304B2 (en) | 2013-03-12 | 2014-03-11 | Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor |
CA2903961A CA2903961A1 (en) | 2013-03-12 | 2014-03-11 | Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor |
BR112015022103A BR112015022103A2 (pt) | 2013-03-12 | 2014-03-11 | composição farmacêutica, método para preparar uma composição farmacêutica, uso de uma composição farmacêutica, e, método para prevenir ou tratar uma doença |
EP14764870.3A EP2977048A4 (en) | 2013-03-12 | 2014-03-11 | Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor |
MX2015012666A MX2015012666A (es) | 2013-03-12 | 2014-03-11 | Preparacion de complejo que incluye valsartan y rosuvastatina calcica y metodo de fabricacion para el mismo. |
CN201480022809.2A CN105163734A (zh) | 2013-03-12 | 2014-03-11 | 包含缬沙坦及罗舒伐他汀钙的复合制剂及其制造方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2013-0026146 | 2013-03-12 | ||
KR20130026146 | 2013-03-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014142521A1 true WO2014142521A1 (ko) | 2014-09-18 |
Family
ID=51537085
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2014/002008 WO2014142521A1 (ko) | 2013-03-12 | 2014-03-11 | 발사르탄 및 로수바스타틴 칼슘을 포함하는 복합 제제 및 이의 제조방법 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20160045497A1 (ko) |
EP (1) | EP2977048A4 (ko) |
JP (1) | JP2016514125A (ko) |
KR (2) | KR20140111982A (ko) |
CN (1) | CN105163734A (ko) |
AU (1) | AU2014230304B2 (ko) |
BR (1) | BR112015022103A2 (ko) |
CA (1) | CA2903961A1 (ko) |
MX (1) | MX2015012666A (ko) |
RU (1) | RU2663460C2 (ko) |
WO (1) | WO2014142521A1 (ko) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160095826A (ko) * | 2015-02-04 | 2016-08-12 | 제이더블유중외제약 주식회사 | 피타바스타틴 또는 이의 약학적으로 허용 가능한 염 및 발사르탄 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물 |
PL3320903T3 (pl) * | 2015-07-08 | 2021-12-06 | Hk Inno.N Corporation | Kompozycja farmaceutyczna zawierająca amlodypinę, walsartan i rosuwastatynę |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5399578A (en) | 1990-02-19 | 1995-03-21 | Ciba-Geigy Corp | Acyl compounds |
USRE37314E1 (en) | 1991-07-01 | 2001-08-07 | Shionogi Seiyaku Kabushiki Kaisha | Pyrimidine derivatives |
US6316460B1 (en) | 2000-01-26 | 2001-11-13 | Astrazeneca Ab | Pharmaceutical compositions |
US20040087484A1 (en) * | 2000-12-01 | 2004-05-06 | Sahota Pritam Singh | Combination of organic compounds |
KR20040106591A (ko) * | 1997-08-29 | 2004-12-17 | 화이자 인코포레이티드 | 아토르바스타틴 및 고혈압치료제를 포함하는 복합 처방 |
KR100582347B1 (ko) * | 2004-12-30 | 2006-05-22 | 한미약품 주식회사 | 3-하이드록시-3-메틸글루타릴 조효소 a 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법 |
KR20100045344A (ko) * | 2008-10-23 | 2010-05-03 | 한올바이오파마주식회사 | 방출성이 제어된 베타 아드레날린 차단제와 HMG-CoA 환원 효소 억제제의 신규 복합 조성물 |
KR100985254B1 (ko) * | 2006-10-30 | 2010-10-04 | 한올바이오파마주식회사 | 방출성이 제어된 안지오텐신―Ⅱ―수용체 차단제와HMG―CoA 환원 효소 억제제의 복합 조성물 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6465502B1 (en) * | 1998-12-23 | 2002-10-15 | Novartis Ag | Additional therapeutic use |
WO2009084040A1 (en) * | 2007-12-28 | 2009-07-09 | Rubicon Research Private Limited | Once a day formulation of angiotensin receptor blockers |
CN101632673B (zh) * | 2008-07-24 | 2011-08-10 | 鲁南制药集团股份有限公司 | 含有氯沙坦、吡格列酮和瑞舒伐他汀的药物组合物及其新用途 |
CN101632672B (zh) * | 2008-07-24 | 2011-01-12 | 鲁南制药集团股份有限公司 | 一种用于治疗高血压的复方药物组合物 |
RU2450823C2 (ru) * | 2009-10-26 | 2012-05-20 | Общество С Ограниченной Ответственностью "Исследовательский Центр "Комкон" | Средство для лечения связанных со стрессовыми условиями заболеваний и расстройств у человека и животных, а также способ лечения и/или профилактики с использованием этого средства |
UY33772A (es) * | 2010-12-09 | 2012-07-31 | Lg Life Sciences Ltd | Composición farmacéutica que comprende clorhidrato de lercanidipina y valsartán como componentes activos y a un método para la preparacion de la misma. |
-
2014
- 2014-03-11 KR KR1020140028375A patent/KR20140111982A/ko active Search and Examination
- 2014-03-11 EP EP14764870.3A patent/EP2977048A4/en not_active Withdrawn
- 2014-03-11 MX MX2015012666A patent/MX2015012666A/es active IP Right Grant
- 2014-03-11 AU AU2014230304A patent/AU2014230304B2/en active Active
- 2014-03-11 RU RU2015143218A patent/RU2663460C2/ru active
- 2014-03-11 US US14/775,422 patent/US20160045497A1/en not_active Abandoned
- 2014-03-11 JP JP2015562916A patent/JP2016514125A/ja active Pending
- 2014-03-11 CN CN201480022809.2A patent/CN105163734A/zh active Pending
- 2014-03-11 BR BR112015022103A patent/BR112015022103A2/pt active Search and Examination
- 2014-03-11 WO PCT/KR2014/002008 patent/WO2014142521A1/ko active Application Filing
- 2014-03-11 CA CA2903961A patent/CA2903961A1/en not_active Abandoned
-
2019
- 2019-09-11 KR KR1020190112921A patent/KR102306005B1/ko active IP Right Grant
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5399578A (en) | 1990-02-19 | 1995-03-21 | Ciba-Geigy Corp | Acyl compounds |
USRE37314E1 (en) | 1991-07-01 | 2001-08-07 | Shionogi Seiyaku Kabushiki Kaisha | Pyrimidine derivatives |
KR20040106591A (ko) * | 1997-08-29 | 2004-12-17 | 화이자 인코포레이티드 | 아토르바스타틴 및 고혈압치료제를 포함하는 복합 처방 |
US6316460B1 (en) | 2000-01-26 | 2001-11-13 | Astrazeneca Ab | Pharmaceutical compositions |
US20040087484A1 (en) * | 2000-12-01 | 2004-05-06 | Sahota Pritam Singh | Combination of organic compounds |
KR100582347B1 (ko) * | 2004-12-30 | 2006-05-22 | 한미약품 주식회사 | 3-하이드록시-3-메틸글루타릴 조효소 a 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법 |
KR100985254B1 (ko) * | 2006-10-30 | 2010-10-04 | 한올바이오파마주식회사 | 방출성이 제어된 안지오텐신―Ⅱ―수용체 차단제와HMG―CoA 환원 효소 억제제의 복합 조성물 |
KR20100045344A (ko) * | 2008-10-23 | 2010-05-03 | 한올바이오파마주식회사 | 방출성이 제어된 베타 아드레날린 차단제와 HMG-CoA 환원 효소 억제제의 신규 복합 조성물 |
Non-Patent Citations (1)
Title |
---|
See also references of EP2977048A4 |
Also Published As
Publication number | Publication date |
---|---|
KR20190108090A (ko) | 2019-09-23 |
KR102306005B1 (ko) | 2021-09-28 |
AU2014230304A8 (en) | 2015-10-15 |
EP2977048A1 (en) | 2016-01-27 |
MX2015012666A (es) | 2016-02-16 |
CA2903961A1 (en) | 2014-09-18 |
RU2663460C2 (ru) | 2018-08-06 |
BR112015022103A2 (pt) | 2017-07-18 |
AU2014230304B2 (en) | 2018-07-05 |
AU2014230304A1 (en) | 2015-10-01 |
RU2015143218A (ru) | 2017-04-17 |
CN105163734A (zh) | 2015-12-16 |
EP2977048A4 (en) | 2017-04-26 |
JP2016514125A (ja) | 2016-05-19 |
KR20140111982A (ko) | 2014-09-22 |
US20160045497A1 (en) | 2016-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2604617C (en) | Composition containing anti-dementia drug | |
KR100836960B1 (ko) | 새로운 나이아신 제어방출형 제제 | |
US20060246003A1 (en) | Composition containing anti-dementia drug | |
WO2017003186A1 (en) | Pharmaceutical complex formulation comprising amlodipine, losartan and rosuvastatin | |
WO2014058188A1 (en) | Combination drug comprising gemigliptin and metformin, and method for the preparation thereof | |
US20110123575A1 (en) | Modified release niacin formulations | |
KR20190108090A (ko) | 발사르탄 및 로수바스타틴 칼슘을 포함하는 복합 제제 및 이의 제조방법 | |
WO2019160243A1 (ko) | 라코사미드를 함유하는 약제학적 서방성 조성물 | |
WO2012077968A2 (en) | Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof | |
US20100285119A1 (en) | Multiparticulate Extended Release Pharmaceutical Composition Of Carbamazepine And Process For Manufacturing The Same | |
KR102389339B1 (ko) | 방출 제어되는 고함량 탐스로신 정제 조성물 및 이의 제조방법 | |
US10335376B2 (en) | Raloxifene sprinkle composition | |
WO2019199132A1 (ko) | 다양한 용량의 레날리도마이드의 경구용 정제 조성물 | |
WO2019004713A2 (ko) | 이바브라딘을 포함하는 서방성 약제학적 조성물 및 이의 제조방법 | |
KR100593252B1 (ko) | 니아신을 함유하는 제어 방출성의 경구용 제제 | |
WO2014038895A1 (ko) | 발사르탄 함유 고형 경구제형 및 그 제조방법 | |
WO2021118004A1 (ko) | 도네페질 및 메만틴을 포함하는 복합 제제 | |
WO2017171483A1 (ko) | 타다라필 및 암로디핀 함유 고형 복합제제 | |
US20120064161A1 (en) | Modified release niacin pharmaceutical formulations | |
MX2007013493A (es) | Composicion que contiene farmaco antidemencia. | |
KR20110132171A (ko) | 니아신 함유 복합 제어방출성 제제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201480022809.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14764870 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2903961 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015/11256 Country of ref document: TR |
|
ENP | Entry into the national phase |
Ref document number: 2015562916 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14775422 Country of ref document: US Ref document number: MX/A/2015/012666 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2014230304 Country of ref document: AU Date of ref document: 20140311 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: IDP00201506213 Country of ref document: ID Ref document number: 2014764870 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2015143218 Country of ref document: RU Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112015022103 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112015022103 Country of ref document: BR Kind code of ref document: A2 Effective date: 20150909 |